Clusterin and pentraxin 3 are markers of severity during febrile neutropenia in adults with haematological malignancies receiving intensive chemotherapy.

ABSTRACT: The identification of predictive biomarkers of severity can improve patient management because febrile neutropenia can be associated with significant morbidity and mortality. We prospectively studied pentraxin 3 (PTX3), a soluble innate immunity receptor, and clusterin (CLU), a chaperone protein that binds extracellular histones during sepsis, in patients experiencing febrile neutropenia after intensive treatment for haematological malignancies. One hundred and forty-three adult patients were included, with 158 episodes of neutropenia analysed. Febrile neutropenia was observed in 119 patients (75%), including 62 without sepsis (group 1; 53%), 42 with sepsis (group 2; 35%) and 14 with severe sepsis/septic shock (group 3; 12%) (missing data, MD): (1) Among these patients, 94 patients had a q

SUBMITTER: Mallebranche C 

PROVIDER: S-EPMC12436219 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature